Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate
- Resource Type
- Authors
- Michèle van Vugt; Elisabeth H. Gisolf; Esmee E. Braam; Ineke W. E. M. Schouten; Julian D. Machiels; Theodora E. M. S. de Vries-Sluijs; Wouter F W Bierman; Petra van Bentum
- Source
- Aids, 33(3), 503-507. LIPPINCOTT WILLIAMS & WILKINS
AIDS, 33(3), 503-507. Lippincott Williams & Wilkins
AIDS (London, England), 33(3), 503-507. Lippincott Williams and Wilkins
- Subject
- 0301 basic medicine
Adult
Male
medicine.medical_specialty
CD4/CD8 RATIO
HEPATITIS-B-VIRUS
Immunology
CD4-CD8 Ratio
HIV Infections
medicine.disease_cause
REVACCINATION
Serology
03 medical and health sciences
0302 clinical medicine
SDG 3 - Good Health and Well-being
Internal medicine
medicine
Immunology and Allergy
Humans
Hepatitis B Vaccines
030212 general & internal medicine
Seroconversion
Hepatitis B Antibodies
Aged
Netherlands
Retrospective Studies
Hepatitis B virus
business.industry
HIV
Retrospective cohort study
ADULTS
Hepatitis B
Middle Aged
vaccines
medicine.disease
vaccination
coinfection
Vaccination
030104 developmental biology
Infectious Diseases
Treatment Outcome
Coinfection
Female
hepatitis B
business
- Language
- English
- ISSN
- 0269-9370
BACKGROUND: Patients with HIV have a poor serological conversion rate with the standard vaccination strategy against hepatitis B virus (HBV) of around 50%. Vaccination with Fendrix confers much better results in these patients. In this study, we tested the effect of revaccination with Fendrix in prior nonresponding patients with HIV and aimed to determine which factors are associated with seroconversion. METHODS: Eight Dutch HIV treatment centers participated in this retrospective study. Patients infected with HIV-1 and nonresponding to prior course of vaccination against HBV (anti-HBs